Pagani O, Regan MM, Fleming GF, et al. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials. SABCS 2017, GS4-02.
Toevoegen atezolizumab bij gemetastaseerd, persisterend of gerecidiveerd cervixcarcinoom
mrt 2024 | Gynaecologische oncologie